Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 9/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21769266 | 0.85 | TLR7 (0.41) | TRPM8TAS1R3TAS1R1TLR8TLR7 | |
| SCHEMBL15469980 | 0.85 | TLR7 (0.41) | TRPM8TAS1R3TAS1R1TLR8TLR7 | |
| SCHEMBL23472108 | 0.84 | CRHR1 (0.41) | TRPM8TAS1R3TAS1R1CRHR1LMNA | |
| SCHEMBL20219523 | 0.80 | CRHR1 (0.40) | CRHR1TLR8TLR7 | |
| SCHEMBL20413264 | 0.80 | CRHR1 (0.40) | CRHR1TLR8TLR7 | |
| SCHEMBL20219370 | 0.79 | CYP2D6 (0.40) | CRHR1TLR8TLR7 | |
| SCHEMBL20413293 | 0.79 | CYP2D6 (0.40) | CRHR1TLR8TLR7 | |
| SCHEMBL20413265 | 0.78 | CRHR1 (0.43) | TRPM8CRHR1MAPTSMN1; SMN2 | |
| SCHEMBL20413303 | 0.76 | TLR7 (0.37) | TRPM8CRHR1MITFLMNAMAPT | |
| SCHEMBL18644353 | 0.76 | TLR7 (0.37) | TRPM8CRHR1TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590928-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-06-09 | — | — | EP | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TRPM8 4192/4885TAS1R3 4063/4885TAS1R1 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.